TuisGSK • LON
add
GSK plc
Vorige sluiting
GBX 1 344,00
Dagwisseling
GBX 1 331,00 - GBX 1 347,50
Jaarwisseling
GBX 1 282,50 - GBX 1 823,50
Markkapitalisasie
55,68 mjd GBP
Gemiddelde volume
8,84 m
P/V-verhouding
21,91
Dividend-opbrengs
4,57%
Primêre beurs
LON
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (GBP) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 8,01 mjd | -1,66% |
Bedryfskoste | 5,02 mjd | 59,83% |
Netto inkomste | -58,00 m | -103,96% |
Netto winsgrens | -0,72 | -104,01% |
Wins per aandeel | 1,29 | 5,78% |
EBITDA | 1,62 mjd | -51,61% |
Effektiewe belastingkoers | -1,56% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (GBP) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 3,21 mjd | -51,94% |
Totale bates | 58,05 mjd | -4,62% |
Totale aanspreeklikheid | 44,60 mjd | -7,56% |
Totale ekwiteit | 13,45 mjd | — |
Uitstaande aandele | 4,08 mjd | — |
Prys om te bespreek | 3,92 | — |
Opbrengs op bates | 2,87% | — |
Opbrengs op kapitaal | 5,54% | — |
Kontantvloei
Netto kontantverandering
| (GBP) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -58,00 m | -103,96% |
Kontant van bedrywe | 2,15 mjd | -2,62% |
Kontant van beleggings | -731,00 m | -48,88% |
Kontant van finansiering | -1,24 mjd | 29,63% |
Netto kontantverandering | 149,00 m | 927,78% |
Beskikbare kontantvloei | 1,89 mjd | 40,47% |
Meer oor
GSK plc is a British multinational pharmaceutical and biotechnology company with headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
GSK is the tenth largest pharmaceutical company and No. 294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it had a market capitalisation of £69 billion, the eighth largest on the London Stock Exchange.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Legacy products developed at GSK include several listed in the World Health Organization's List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine and zidovudine. Wikipedia
Gestig
27 Des. 2000
Webwerf
Werknemers
70 212
